23:23 , Dec 1, 2017 |  BC Extra  |  Clinical News

Bayer reports mortality signal with Xofigo in early CRPC

Bayer AG (Xetra:BAYN) said an IDMC observed more fractures and deaths among patients treated with Xofigo radium-223 dichloride vs. placebo in the Phase III ERA223 trial to treat metastatic castration-resistant prostate cancer. Bayer said it...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
07:00 , May 23, 2016 |  BioCentury  |  Finance

Home sweet krone

Wilson Therapeutics AB (SSE:WTX) opted to list locally in Stockholm and secured enough cash to ignore the markets until 2020, which is when it plans to hire a sales force for its rare disease asset....
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Bayer sales and marketing update

The U.K.’s NICE issued draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases who have received treatment with docetaxel....
02:10 , Feb 27, 2015 |  BC Extra  |  Company News

Management tracks

Ophthalmology company Ohr Pharmaceutical Inc. (NASDAQ:OHRP) hired Avner Ingerman as chief clinical officer. Ingerman was formerly VP of ophthalmology at Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Cancer vaccine play Targovax A/S (Lysaker, Norway) hired Oystein Soug as...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Navidea management update

Navidea Biopharmaceuticals Inc. (NYSE-M:NAVB), Dublin, Ohio   Business: Diagnostic   Hired: Thomas Klima as SVP and chief commercial officer, formerly head of sales at Algeta ASA, which Bayer AG acquired; and Michael Tomblyn as executive...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Fresh fund, same plan

Advent Venture Partners plans to stick with its long-standing investment strategy for its second dedicated life sciences fund, Advent Life Sciences Fund II, which the firm closed last week with £145.5 million ($234.3 million). "The investment...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Bayer pharmaceuticals, other news

Bayer said it will focus on its life science businesses and spin out its material sciences division, Bayer MaterialScience, into a separate publicly listed company in the next 12-18 months. The pharma said the major...
02:44 , Sep 19, 2014 |  BC Extra  |  Company News

Bayer to focus on life sciences, spinning out material science unit

Bayer AG (Xetra:BAYN) said it will focus on its life science businesses and spin out its material sciences division into a separate publicly listed company in the next 12-18 months. The pharma said the major...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Blueprint Medicines management update

Blueprint Medicines, Cambridge, Mass.   Business: Cancer   Hired: Jeffrey Albers as CEO and a director, formerly U.S. president at Algeta ASA, which Bayer AG acquired; he succeeds co-founder and interim CEO Alexis Borisy, who...